The
Medicines Company MDCO today reported presentation and
publication of a pooled analysis of three Phase III clinical trials
of an investigational intravenous (IV) antiplatelet, cangrelor. The
trials compared IV cangrelor to either oral clopidogrel or placebo
for prevention of thrombotic (clotting) complications during and
after percutaneous coronary intervention (PCI). The findings of the
pooled CHAMPION program confirm the results of the CHAMPION PHOENIX
trial presented and published in April 2013.
This pre-specified, pooled analysis of patient-level data from
CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX was presented
at the European Society of Cardiology today and concurrently
published in The Lancet.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in